Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma

Virchows Arch. 2017 Jan;470(1):113-117. doi: 10.1007/s00428-016-2041-7. Epub 2016 Nov 25.

Authors

Samantha Kendrick¹, Lisa M Rimsza², David W Scott³, Graham W Slack⁴, Pedro Farinha⁴, King L Tan⁴, Daniel Persky⁵, Soham Puvvada⁵, Joseph M Connors³, Laurie Sehn³, Randy D Gascoyne^{3

4}, Monika Schmelz⁶

Affiliations

¹ Department of Pathology, University of Arizona, P.O. Box 24-5043, 1501 N Campbell Ave, Tucson, AZ, 85724, USA.
² Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA.
³ Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.
⁴ Department of Pathology, British Columbia Cancer Agency, Vancouver, Canada.
⁵ University of Arizona Cancer Center, Tucson, AZ, USA.
⁶ Department of Pathology, University of Arizona, P.O. Box 24-5043, 1501 N Campbell Ave, Tucson, AZ, 85724, USA. schmelz@pathology.arizona.edu.

PMID: 27888357
DOI: 10.1007/s00428-016-2041-7

No abstract available

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cytoplasm / metabolism*
Disease-Free Survival
Female
Histocompatibility Antigens Class II / immunology*
Humans
Lymphoma, Large B-Cell, Diffuse / diagnosis*
Lymphoma, Large B-Cell, Diffuse / immunology*
Lymphoma, Large B-Cell, Diffuse / metabolism
Lymphoma, Large B-Cell, Diffuse / pathology
Male
Middle Aged
Prognosis
Young Adult

Substances

Antibodies, Monoclonal, Murine-Derived
Histocompatibility Antigens Class II

Grants and funding

P30 CA023074/CA/NCI NIH HHS/United States